Antimetastatic effectiveness of amifostine therapy following surgical removal of Sa-NH tumors in mice.

[1]  L. Oberley,et al.  Delayed Cytoprotection after Enhancement of Sod2 (MnSOD) Gene Expression in SA-NH Mouse Sarcoma Cells Exposed to WR-1065, the Active Metabolite of Amifostine , 2002, Radiation research.

[2]  R. Weichselbaum,et al.  Activation of the nuclear transcription factor κB (NFκB) and differential gene expression in U87 glioma cells after exposure to the cytoprotector amifostine , 2002 .

[3]  R. Weichselbaum,et al.  Inhibition of spontaneous metastases formation by amifostine , 2002, International journal of cancer.

[4]  D. Hallahan,et al.  Activation of NFκB and MnSOD gene expression by free radical scavengers in human microvascular endothelial cells , 2001 .

[5]  C. Griffiths,et al.  Psoriasis: the future , 2001, The British journal of dermatology.

[6]  R. Weichselbaum,et al.  Angiostatin induces mitotic cell death of proliferating endothelial cells. , 2000, Molecular cell biology research communications : MCBRC.

[7]  E. Small,et al.  Hormone-refractory prostate cancer: an evolving standard of care. , 1999, Seminars in oncology.

[8]  A. List.  Use of amifostine in hematologic malignancies, myelodysplastic syndrome, and acute leukemia. , 1999, Seminars in oncology.

[9]  L. Milas,et al.  Chemopreventive doses of amifostine confer no cytoprotection to tumor nodules growing in the lungs of mice treated with cyclophosphamide. , 1999, Seminars in oncology.

[10]  P. Hogg,et al.  Angiostatin Formation Involves Disulfide Bond Reduction and Proteolysis in Kringle 5 of Plasmin* , 1999, The Journal of Biological Chemistry.

[11]  O. Musso,et al.  Homeostatic control of angiogenesis: A newly identified function of the liver? , 1999, Hepatology.

[12]  L. Milas,et al.  Lack of correlation between mitotic arrest or apoptosis and antitumor effect of docetaxel , 1999, Cancer Chemotherapy and Pharmacology.

[13]  L. Oberley,et al.  Overexpression of manganese superoxide dismutase in DU145 human prostate carcinoma cells has multiple effects on cell phenotype , 1998, The Prostate.

[14]  P. Hogg,et al.  Generation of Angiostatin by Reduction and Proteolysis of Plasmin , 1997, The Journal of Biological Chemistry.

[15]  L. Oberley,et al.  Transfection and expression of MnSOD cDNA decreases tumor malignancy of human oral squamous carcinoma SCC-25 cells. , 1997, Human gene therapy.

[16]  M. Stack,et al.  Human prostate carcinoma cells express enzymatic activity that converts human plasminogen to the angiogenesis inhibitor, angiostatin. , 1996, Cancer research.

[17]  L. Milas,et al.  Antimutagenic effects of amifostine: clinical implications. , 1996, Seminars in oncology.

[18]  O. Volpert,et al.  Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats. , 1996, The Journal of clinical investigation.

[19]  S. De Flora,et al.  Inhibition of invasion, gelatinase activity, tumor take and metastasis of malignant cells by N‐acetylcysteine , 1995, International journal of cancer.

[20]  D. S. St. Clair,et al.  Suppression of fibrosarcoma metastasis by elevated expression of manganese superoxide dismutase. , 1994, Cancer research.

[21]  I. Basic,et al.  The radioprotector WR-2721 reduces neutron-induced mutations at the hypoxanthine-guanine phosphoribosyl transferase locus in mouse splenocytes when administered prior to or following irradiation. , 1992, Carcinogenesis.

[22]  B. Carnes,et al.  Protection against late effects of radiation by S-2-(3-aminopropylamino)-ethylphosphorothioic acid. , 1991, Cancer research.

[23]  A. Kanclerz,et al.  Influence of misonidazole, SR-2508, RSU-1069 and WR-2721 on spontaneous metastases in C57BL mice. , 1988, International journal of radiation oncology, biology, physics.

[24]  P. Tofilon,et al.  Effect of the radiosensitizer misonidazole and the radioprotector diethyldithiocarbamate on spontaneous metastasis formation of murine tumors. , 1986, International journal of radiation oncology, biology, physics.

[25]  V. Ferrans,et al.  Mechanism of the protective activity of ICRF-187 against alloxan-induced diabetes in mice. , 1986, Research communications in chemical pathology and pharmacology.

[26]  A. Cerami,et al.  Protein binding of N-2-mercaptoethyl-1,3-diaminopropane via mixed disulfide formation after oral administration of WR 2721. , 1982, The Journal of pharmacology and experimental therapeutics.

[27]  A. Cerami,et al.  Studies on the reduction of sputum viscosity in cystic fibrosis using an orally absorbed protected thiol. , 1980, The Journal of pharmacology and experimental therapeutics.

[28]  J. Walker,et al.  Tumor rejection in experimental animals treated with radioprotective thiols. , 1975, Cancer research.

[29]  O. Yukawa,et al.  Damages in the microsomal drug metabolizing enzyme system after partial x-irradiation of rat liver. , 1974, Radiation research.

[30]  W. Dröge.  Free radicals in the physiological control of cell function. , 2002, Physiological reviews.

[31]  Y. Kataoka,et al.  Differential activation of nuclear transcription factor kappaB, gene expression, and proteins by amifostine's free thiol in human microvascular endothelial and glioma cells. , 2002, Seminars in radiation oncology.

[32]  C. Karakousis,et al.  Study of antiangiogenic agents with possible therapeutic applications in neoplastic disorders and macular degeneration. , 2000, Journal of medicine.

[33]  Y. Kataoka,et al.  Amifostine: Mechanisms of Action Underlying Cytoprotection and Chemoprevention , 2000, Drug metabolism and drug interactions.

[34]  W. Stetler-Stevenson,et al.  Matrix metalloproteinases and metastasis , 1999, Cancer Chemotherapy and Pharmacology.

[35]  B. Zetter,et al.  Angiogenesis and tumor metastasis. , 1998, Annual review of medicine.

[36]  D. Grdina,et al.  Radiation protectors: the unexpected benefits. , 1989, Drug metabolism reviews.